Tebufenozide

CAS No. 112410-23-8

Tebufenozide( —— )

Catalog No. M23317 CAS No. 112410-23-8

Tebufenozide is a novel nonsteroidal ecdysone agonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 41 In Stock
25MG 37 In Stock
50MG 60 In Stock
100MG 90 In Stock
200MG 133 In Stock
500MG 221 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Tebufenozide
  • Note
    Research use only, not for human use.
  • Brief Description
    Tebufenozide is a novel nonsteroidal ecdysone agonist.
  • Description
    Tebufenozide is a novel nonsteroidal ecdysone agonist. It shows good efficacy and playing an increasingly important role in the control of Lepidopteran pests.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    112410-23-8
  • Formula Weight
    352.48
  • Molecular Formula
    C22H28N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:125 mg/mL (354.64 mM; Need ultrasonic)
  • SMILES
    CCc(cc1)ccc1C(NN(C(C)(C)C)C(c1cc(C)cc(C)c1)=O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Yun-Sik L , Sung-Eun L , Jino S , et al. Toxicity effects and biomarkers of tebufenozide exposure in Yuukianura szeptyckii (Collembola: Neanuridae)[J]. Environmental Geochemistry & Health, 2018:1-12.
molnova catalog
related products
  • 2-Deoxy-2-fluoro-bet...

    2'-Deoxy-2'-fluoro-beta-D-arabinoguanosine is a purine nucleoside analog with a broad spectrum of antitumor activity, targeting malignant tumors of the inert lymphatic system and inducing apoptosis.

  • TAS6417

    TAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC.

  • Britannin

    Britannin a sesquiterpene lactone inhibits proliferation and induces apoptosis through the mitochondrial signaling pathway in human breast cancer cells.